Klaus Dugi, Vandria CEO December 2, 2025 03:00 AM EST Updated 06:58 AM FinancingR&D Swiss biotech plots Se­ries B raise to ad­vance Alzheimer’s drug in­to Phase 2 Ayisha Sharma News Reporter Two years af­ter com­ing out of stealth, Van­dria said its in­ves­ti­ga­tion­al Alzheimer’s drug has shown promise in an ear­ly tri­al in hu­mans … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER ENDPOINTS CAREERS Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote VIEW JOB OFFER post your job now